Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2008

01-07-2008 | Preclinical Study

Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-β1) increase invasion rate of tumor cells: a population study

Authors: Theresa M. Casey, Jonathan Eneman, Abigail Crocker, Jeffrey White, Joseph Tessitore, Mary Stanley, Seth Harlow, Janice Y. Bunn, Donald Weaver, Hyman Muss, Karen Plaut

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Login to get access

Abstract

Cancer associated fibroblasts (CAFs) are believed to promote tumor growth and progression. Our objective was to measure the effect of TGF-β1 on fibroblasts isolated from invasive breast cancer patients. Fibroblasts were isolated from tissue obtained at surgery from patients with invasive breast cancer (CAF; n = 28) or normal reduction mammoplasty patients (normal; n = 10). Myofibroblast activation was measured by counting cells immunostained for smooth muscle alpha actin (ACTA2) in cultures ± TGF-β1. Conditioned media (CM) was collected for invasion assays and RNA was isolated from cultures incubated in media ± TGF-β1 for 24 h. Q-PCR was used to measure expression of cyclin D1, fibronectin, laminin, collagen I, urokinase, stromelysin-1, and ACTA2 genes. Invasion rate was measured in chambers plated with MDA-MB-231 cells and exposed to CM in the bottom chamber; the number of cells that invaded into the bottom chamber was counted. Wilcox Rank Sum tests were used to evaluate differences in CAFs and normal fibroblasts and the effect of TGF-β1. There was no difference in percent myofibroblasts or invasion rate between normal and CAF cultures. However, TGF-β1 significantly increased the percent of myofibroblasts (P < 0.01) and invasion rate (P = 0.02) in CAF cultures. Stromelysin-1 expression was significantly higher in normal versus CAF cultures (P < 0.01). TGF-β1 significantly increased ACTA2 expression in both normal and CAF cultures (P < 0.01). Expression of fibronectin and laminin was significantly increased by TGF-β in CAF cultures (P < 0.01). CAFs were measurably different from normal fibroblasts in response to TGF-β1, suggesting that TGF-β stimulates changes in CAFs that foster tumor invasion.
Literature
1.
go back to reference Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer Statistics, 2007. CA Cancer J Clin 57:43–66PubMedCrossRef Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer Statistics, 2007. CA Cancer J Clin 57:43–66PubMedCrossRef
3.
go back to reference Schnitt S, Guidi A (2000) Pathology of invasive breast cancer. In: Harris JR, Lippman ME, Murrow M, Osborn CK (eds) Diseases of the breast, 2nd edn. Lippincott, Williams, and Wilkins, NY, p 425 Schnitt S, Guidi A (2000) Pathology of invasive breast cancer. In: Harris JR, Lippman ME, Murrow M, Osborn CK (eds) Diseases of the breast, 2nd edn. Lippincott, Williams, and Wilkins, NY, p 425
5.
go back to reference Noel A, Foidart J-M (1998) The role of stroma in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia V3:215–225CrossRef Noel A, Foidart J-M (1998) The role of stroma in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia V3:215–225CrossRef
6.
go back to reference Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR (2002) Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 62:3298–3307PubMed Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR (2002) Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 62:3298–3307PubMed
8.
go back to reference Condeelis J, Segall JE (2003) Intravital imaging of cell movement in tumours. Nat Rev Cancer 3:921–930PubMedCrossRef Condeelis J, Segall JE (2003) Intravital imaging of cell movement in tumours. Nat Rev Cancer 3:921–930PubMedCrossRef
9.
go back to reference Robinson S, Silberstein G, Daniel CW (1992) Evidence supporting a role for TGF-beta isoforms in growth regulation and functional differentiation of the mouse mammary gland. In: Picciano MF, Lonnerdal B (eds) Mechanisms regulating lactation and infant nutrient utilization. Wiley-Liss, New York, pp 43–52 Robinson S, Silberstein G, Daniel CW (1992) Evidence supporting a role for TGF-beta isoforms in growth regulation and functional differentiation of the mouse mammary gland. In: Picciano MF, Lonnerdal B (eds) Mechanisms regulating lactation and infant nutrient utilization. Wiley-Liss, New York, pp 43–52
10.
go back to reference Faler B, Macsata R, Plummer D, Mishra L, Sidawy A (2006) Transforming growth factor-beta and wound healing. Perspect Vasc Surg Endovasc Ther 18:55–62PubMedCrossRef Faler B, Macsata R, Plummer D, Mishra L, Sidawy A (2006) Transforming growth factor-beta and wound healing. Perspect Vasc Surg Endovasc Ther 18:55–62PubMedCrossRef
11.
go back to reference O’Kane S, Ferguson MWJ (1997) Transforming growth factor [beta]s and wound healing. Int J Biochem Cell Biol 29:63–78PubMedCrossRef O’Kane S, Ferguson MWJ (1997) Transforming growth factor [beta]s and wound healing. Int J Biochem Cell Biol 29:63–78PubMedCrossRef
12.
13.
go back to reference Fleisch MC, Maxwell CA, Barcellos-Hoff M-H (2006) The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocrinology 13:379–400 Fleisch MC, Maxwell CA, Barcellos-Hoff M-H (2006) The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocrinology 13:379–400
14.
go back to reference Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan R, Zborowska E, Kinzler K, Vogelstein B (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 268:1336–1338PubMedCrossRef Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan R, Zborowska E, Kinzler K, Vogelstein B (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 268:1336–1338PubMedCrossRef
15.
go back to reference Hahn S, Schutte M, Hoque A, Moskaluk C, da Costa L, Rozenblum E, Weinstein C, Fischer A, Yeo C, Hruban R, Kern S (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353PubMedCrossRef Hahn S, Schutte M, Hoque A, Moskaluk C, da Costa L, Rozenblum E, Weinstein C, Fischer A, Yeo C, Hruban R, Kern S (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353PubMedCrossRef
16.
go back to reference Grady W, Myeroff L, Swinler S, Rajput A, Thiagalingam S, Lutterbaugh J, Neumann A, Brattain M, Chang J, Kim S, Kinzler K, Vogelstein B, Willson J, Markowitz S (1999) Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 50:320–324 Grady W, Myeroff L, Swinler S, Rajput A, Thiagalingam S, Lutterbaugh J, Neumann A, Brattain M, Chang J, Kim S, Kinzler K, Vogelstein B, Willson J, Markowitz S (1999) Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 50:320–324
17.
go back to reference Grady W, Rajput A, Myeroff L, Liu D, Kwon K, Willis J, Markowitz S (1998) Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58:3101–3104PubMed Grady W, Rajput A, Myeroff L, Liu D, Kwon K, Willis J, Markowitz S (1998) Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58:3101–3104PubMed
18.
go back to reference Barlow J, Yandell D, Weaver D, Casey T, Plaut K (2003) Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors. Breast Cancer Res Treat 79:149–159PubMedCrossRef Barlow J, Yandell D, Weaver D, Casey T, Plaut K (2003) Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors. Breast Cancer Res Treat 79:149–159PubMedCrossRef
19.
go back to reference Tomita S, Deguchi S, Miyaguni T, Muto Y, Tamamoto T, Toda T (1999) Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features. Breast Cancer Res Treat 53:33–39PubMedCrossRef Tomita S, Deguchi S, Miyaguni T, Muto Y, Tamamoto T, Toda T (1999) Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features. Breast Cancer Res Treat 53:33–39PubMedCrossRef
20.
go back to reference Anbazhagan R, Bornman DM, Johnston JC, Westra WH, Gabrielson E (1999) The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma. Cancer Res 59:3363–3364PubMed Anbazhagan R, Bornman DM, Johnston JC, Westra WH, Gabrielson E (1999) The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma. Cancer Res 59:3363–3364PubMed
21.
go back to reference Reiss M, Barcellos-Hoff MH (1997) Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45:81–95PubMedCrossRef Reiss M, Barcellos-Hoff MH (1997) Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45:81–95PubMedCrossRef
22.
go back to reference Roberts A, Wakefield L (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100:8621–8623PubMedCrossRef Roberts A, Wakefield L (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100:8621–8623PubMedCrossRef
23.
go back to reference Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM (2003) TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112:1116–1124PubMed Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM (2003) TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112:1116–1124PubMed
24.
go back to reference Ghellal A, Li C, Hayes M, Byrne G, Bundred N, Kumar S (2000) Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res 20:4413–4418PubMed Ghellal A, Li C, Hayes M, Byrne G, Bundred N, Kumar S (2000) Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res 20:4413–4418PubMed
25.
go back to reference Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ (2001) Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg 136:937–940PubMedCrossRef Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ (2001) Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg 136:937–940PubMedCrossRef
26.
go back to reference Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA (1992) Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52:6949–6952PubMed Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA (1992) Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52:6949–6952PubMed
27.
go back to reference Walker RA, Dearing SJ, Gallacher B (1994) Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer 69:1160–1165PubMed Walker RA, Dearing SJ, Gallacher B (1994) Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer 69:1160–1165PubMed
28.
go back to reference Dumont N, Arteaga CL (2000) Transforming growth factor-beta and breast cancer: tumor promoting effects of transforming growth factor-beta. Breast Cancer Res 2:125–132PubMedCrossRef Dumont N, Arteaga CL (2000) Transforming growth factor-beta and breast cancer: tumor promoting effects of transforming growth factor-beta. Breast Cancer Res 2:125–132PubMedCrossRef
29.
go back to reference Ronnov-Jessen L, Petersen OW (1993) Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 68:696–707PubMed Ronnov-Jessen L, Petersen OW (1993) Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 68:696–707PubMed
30.
go back to reference Sieuwerts A, Klijn J, Henzen-Logmans S, Foekens J (1999) Cytokine regulated urokinase type plasminogen activator (uPA) production by human breast fibroblasts in vitro. Breast Cancer Res Treat 55:9–20PubMedCrossRef Sieuwerts A, Klijn J, Henzen-Logmans S, Foekens J (1999) Cytokine regulated urokinase type plasminogen activator (uPA) production by human breast fibroblasts in vitro. Breast Cancer Res Treat 55:9–20PubMedCrossRef
31.
go back to reference Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171PubMedCrossRef Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171PubMedCrossRef
32.
go back to reference Geiser AG, Burmester JK, Webbink R, Roberts AB, Sporn MB (1992) Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. J Biol Chem 267:2588–2593PubMed Geiser AG, Burmester JK, Webbink R, Roberts AB, Sporn MB (1992) Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. J Biol Chem 267:2588–2593PubMed
33.
go back to reference Stampfer MR, Yaswen P, Alhadeff M, Hosoda J (1993) TGF beta induction of extracellular matrix associated proteins in normal and transformed human mammary epithelial cells in culture is independent of growth effects. J Cell Physiol 155:210–221PubMedCrossRef Stampfer MR, Yaswen P, Alhadeff M, Hosoda J (1993) TGF beta induction of extracellular matrix associated proteins in normal and transformed human mammary epithelial cells in culture is independent of growth effects. J Cell Physiol 155:210–221PubMedCrossRef
34.
go back to reference Delany AM, Canalis E (2001) The metastasis-associated metalloproteinase stromelysin-3 is induced by transforming growth factor-beta in osteoblasts and fibroblasts. Endocrinology 142:1561–1566PubMedCrossRef Delany AM, Canalis E (2001) The metastasis-associated metalloproteinase stromelysin-3 is induced by transforming growth factor-beta in osteoblasts and fibroblasts. Endocrinology 142:1561–1566PubMedCrossRef
35.
go back to reference Pilkington MF, Sims SM, Dixon SJ (2001) Transforming growth factor-beta induces osteoclast ruffling and chemotaxis: potential role in osteoclast recruitment. J Bone Miner Res 16:1237–1247PubMedCrossRef Pilkington MF, Sims SM, Dixon SJ (2001) Transforming growth factor-beta induces osteoclast ruffling and chemotaxis: potential role in osteoclast recruitment. J Bone Miner Res 16:1237–1247PubMedCrossRef
36.
go back to reference Corsino P, Davis B, Law M, Chytil A, Forrester E, Norgaard P, Teoh N, Law B (2007) Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor {beta} resistance and acquire paracrine mitogenic stimulation during progression. Cancer Res 67:3135–3144PubMedCrossRef Corsino P, Davis B, Law M, Chytil A, Forrester E, Norgaard P, Teoh N, Law B (2007) Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor {beta} resistance and acquire paracrine mitogenic stimulation during progression. Cancer Res 67:3135–3144PubMedCrossRef
37.
go back to reference Plaut K, Bramley A, Casey T, Muss H (2004) Patients with recurrent breast cancer have higher expression of TGF-B1 in primary tumor. In: San Antonio breast cancer symposium, San Antonio, TX Plaut K, Bramley A, Casey T, Muss H (2004) Patients with recurrent breast cancer have higher expression of TGF-B1 in primary tumor. In: San Antonio breast cancer symposium, San Antonio, TX
38.
go back to reference Singer C, Kronsteiner N, Marton E, Kubista M, Cullen K, Hirtenlehner K, Seifert M, Kubista E (2002) MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 72:69–77PubMedCrossRef Singer C, Kronsteiner N, Marton E, Kubista M, Cullen K, Hirtenlehner K, Seifert M, Kubista E (2002) MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 72:69–77PubMedCrossRef
39.
go back to reference Basset P, Wolf C, Chambon P (1993) Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat 24:185–193PubMedCrossRef Basset P, Wolf C, Chambon P (1993) Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat 24:185–193PubMedCrossRef
40.
go back to reference Tang Y, Kesavan P, Nakada MT, Yan L (2004) Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2:73–80PubMed Tang Y, Kesavan P, Nakada MT, Yan L (2004) Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2:73–80PubMed
41.
go back to reference Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL (2004) TGF-{beta} Signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848–851PubMedCrossRef Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL (2004) TGF-{beta} Signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848–851PubMedCrossRef
42.
go back to reference Ronnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76:69–125PubMed Ronnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76:69–125PubMed
43.
go back to reference Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL (2005) Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 24:5053–5068PubMedCrossRef Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL (2005) Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 24:5053–5068PubMedCrossRef
44.
go back to reference Parrott JA, Nilsson E, Mosher R, Magrane G, Albertson D, Pinkel D, Gray JW, Skinner MK (2001) Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Mol Cell Endocrinol 175:29–39PubMedCrossRef Parrott JA, Nilsson E, Mosher R, Magrane G, Albertson D, Pinkel D, Gray JW, Skinner MK (2001) Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Mol Cell Endocrinol 175:29–39PubMedCrossRef
45.
go back to reference Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology (1991) 19:403–410. Histopathology 41:151 Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology (1991) 19:403–410. Histopathology 41:151
46.
go back to reference Elston C, Ellis I (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 19:403–410CrossRef Elston C, Ellis I (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 19:403–410CrossRef
47.
go back to reference Speirs V, White MC, Green AR (1996) Collagenase III: a superior enzyme for complete disaggregation and improved viability of normal and malignant human breast tissue. In vitro Cell Dev Biol Anim 32:72–74PubMedCrossRef Speirs V, White MC, Green AR (1996) Collagenase III: a superior enzyme for complete disaggregation and improved viability of normal and malignant human breast tissue. In vitro Cell Dev Biol Anim 32:72–74PubMedCrossRef
48.
go back to reference Zarzynska J, Gajewska M, Motyl T (2005) Effects of hormones and growth factors on TGF-beta1 expression in bovine mammary epithelial cells. J Dairy Res 72:39–48PubMedCrossRef Zarzynska J, Gajewska M, Motyl T (2005) Effects of hormones and growth factors on TGF-beta1 expression in bovine mammary epithelial cells. J Dairy Res 72:39–48PubMedCrossRef
49.
go back to reference Van Susante J, Buma P, Van Beuningen H, Van den Berg W, Veth R (2000) Responsiveness of bovine chondrocytes to growth factors in medium with different serum concentrations. J Orthoped Res 18:68–77CrossRef Van Susante J, Buma P, Van Beuningen H, Van den Berg W, Veth R (2000) Responsiveness of bovine chondrocytes to growth factors in medium with different serum concentrations. J Orthoped Res 18:68–77CrossRef
50.
go back to reference van Roozendaal C, Klijn J, van Ooijen B, Claassen C, Eggermont A, Henzen-Logmans S, Foekens J (1995) Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinol 111:1–6PubMedCrossRef van Roozendaal C, Klijn J, van Ooijen B, Claassen C, Eggermont A, Henzen-Logmans S, Foekens J (1995) Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinol 111:1–6PubMedCrossRef
51.
go back to reference Kratochwil K (1969) Organ specificity in mesenchymal induction demonstrated in the embryonic development of the mammary gland of the mouse. Dev Biol 20:46–71PubMedCrossRef Kratochwil K (1969) Organ specificity in mesenchymal induction demonstrated in the embryonic development of the mammary gland of the mouse. Dev Biol 20:46–71PubMedCrossRef
52.
go back to reference Barcellos-Hoff MH, Ravani SA (2000) Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 60:1254–1260PubMed Barcellos-Hoff MH, Ravani SA (2000) Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 60:1254–1260PubMed
53.
go back to reference Barcellos-Hoff MH (1993) Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 53:3880–3886PubMed Barcellos-Hoff MH (1993) Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 53:3880–3886PubMed
54.
go back to reference Barcellos-Hoff MH (1998) The potential influence of radiation-induced microenvironments in neoplastic progression. J Mammary Gland Biol Neoplasia 3:165–175PubMedCrossRef Barcellos-Hoff MH (1998) The potential influence of radiation-induced microenvironments in neoplastic progression. J Mammary Gland Biol Neoplasia 3:165–175PubMedCrossRef
55.
go back to reference Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA (2000) Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 60:2562–2566PubMed Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA (2000) Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 60:2562–2566PubMed
56.
go back to reference Finak G, Sadekova S, Pepin F, Hallett M, Meterissian S, Halwani F, Khetani K, Souleimanova M, Zabolotny B, Omeroglu A, Park M (2006) Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 8:R58PubMedCrossRef Finak G, Sadekova S, Pepin F, Hallett M, Meterissian S, Halwani F, Khetani K, Souleimanova M, Zabolotny B, Omeroglu A, Park M (2006) Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 8:R58PubMedCrossRef
57.
go back to reference Bodey B, Bodey B Jr., Siegel SE, Kaiser HE (2001) Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas. Anticancer Res 21:2021–2028PubMed Bodey B, Bodey B Jr., Siegel SE, Kaiser HE (2001) Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas. Anticancer Res 21:2021–2028PubMed
58.
go back to reference Sympson CJ, Bissell MJ, Werb Z (1995) Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol 6:159–163PubMedCrossRef Sympson CJ, Bissell MJ, Werb Z (1995) Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol 6:159–163PubMedCrossRef
59.
go back to reference Thomasset N, Lochter A, Sympson CJ, Lund LR, Williams DR, Behrendtsen O, Werb Z, Bissell MJ (1998) Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am J Pathol 153:457–467PubMed Thomasset N, Lochter A, Sympson CJ, Lund LR, Williams DR, Behrendtsen O, Werb Z, Bissell MJ (1998) Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am J Pathol 153:457–467PubMed
60.
go back to reference Clark EA, Goiub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535PubMedCrossRef Clark EA, Goiub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535PubMedCrossRef
61.
go back to reference Nielsen B, Sehested M, Timshel S, Pyke C, Danø K (1996) Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74:168–177PubMed Nielsen B, Sehested M, Timshel S, Pyke C, Danø K (1996) Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74:168–177PubMed
Metadata
Title
Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-β1) increase invasion rate of tumor cells: a population study
Authors
Theresa M. Casey
Jonathan Eneman
Abigail Crocker
Jeffrey White
Joseph Tessitore
Mary Stanley
Seth Harlow
Janice Y. Bunn
Donald Weaver
Hyman Muss
Karen Plaut
Publication date
01-07-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9684-7

Other articles of this Issue 1/2008

Breast Cancer Research and Treatment 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine